TriSalus Life Sciences (TLSI) Change in Accured Expenses (2021 - 2026)

TriSalus Life Sciences has reported Change in Accured Expenses for 6 years, with the latest figure at $160000.0 in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 90.15% year-over-year to $160000.0; the trailing twelve-month figure through Mar 2026 stood at $556000.0 (up 122.65% YoY), and the FY2025 full-year result was $2.0 million, up 146.08% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $160000.0, down from $692000.0 in the prior quarter.
• The five-year high for Change in Accured Expenses was $5.4 million in Q4 2023, with the low at -$4.6 million in Q3 2023.
• Historically, Change in Accured Expenses has averaged $345882.4 across 5 years, with a median of $214728.0 in 2022.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 1046.1% — and 2024, when it tumbled 1486.36%.
• TriSalus Life Sciences' Change in Accured Expenses stood at $4.1 million in 2022, then jumped by 30.69% to $5.4 million in 2023, then slumped by 94.43% to $301000.0 in 2024, then surged by 129.9% to $692000.0 in 2025, then slumped by 76.88% to $160000.0 in 2026.
• The last three Change in Accured Expenses figures came in at $160000.0 (Q1 2026), $692000.0 (Q4 2025), and $1.5 million (Q3 2025), per Business Quant data.